In pan-cancer studies, the mean prevalence rates were 0.54% for FH mutations, 7.75% for copy number alteration (CNA) deletions (including shallow and deep deletions), and 5% for 1q arm loss (Supplementary Table S1). The gene discussed is FH; the disease is cancer.